Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
Several weeks ago, we were fortunate enough to have Dr. Mary Pinder (alternately referred to as Pinder-Schenck) from the H. Lee Moffitt Cancer Center in Tampa join as the first of two speakers reviewing highlights in thoracic oncology from ASCO. She covered several key presentations in small cell lung cancer, early stage non-small cell lung cancer, and mesothelioma. Here's the audio and video versions of the podcast, along with the transcript and figures (a zip file to decompress, since it was too big in unzipped form to upload) for this program:
[powerpress]
pinder-asco-2011-highlights-sclc-early-stage-nsclc-and-meso-audio-podcast
pinder-asco-2011-highlights-sclc-early-stage-nsclc-and-meso-transcript
pinder-asco-2011-highlights-sclc-early-stage-nsclc-and-meso-figures
This program will be followed by Dr. Nasser Hanna's presentation of the highlights from advanced NSCLC at ASCO 2011, and then question and answer time as an additional podcast. The live webinar, as well as all of these podcasts, were developed in partnership with LUNGevity Foundation. We're very grateful for their support.
And for those of you reminded of how much you like Dr. Pinder, don't worry -- she's coming back for September.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…